Adipose tissue as a target for second-generation (atypical) antipsychotics: A molecular view

Schizophrenia is a neuropsychiatric disorder that chronically affects 21 million people worldwide. Secondgeneration antipsychotics (SGAs) are the cornerstone in the management of schizophrenia. However, despite their efficacy in counteracting both positive and negative symptomatology of schizophreni...

Descripción completa

Detalles Bibliográficos
Autores: Ferreira, Vitor, Grajales, Diana, Valverde, Ángela M.
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/692576
Acceso en línea:http://hdl.handle.net/10486/692576
https://dx.doi.org/10.1016/j.bbalip.2019.158534
Access Level:acceso abierto
Palabra clave:Adipose tissue
Antipsychotics
Schizophrenia
Lipid metabolism
Adipocyte differentiation
Thermogenesis
Browning
Medicina
Descripción
Sumario:Schizophrenia is a neuropsychiatric disorder that chronically affects 21 million people worldwide. Secondgeneration antipsychotics (SGAs) are the cornerstone in the management of schizophrenia. However, despite their efficacy in counteracting both positive and negative symptomatology of schizophrenia, recent clinical observations have described an increase in the prevalence of metabolic disturbances in patients treated with SGAs, including abnormal weight gain, hyperglycemia and dyslipidemia. While the molecular mechanisms responsible for these side-effects remain poorly understood, increasing evidence points to a link between SGAs and adipose tissue depots of white, brown and beige adipocytes. In this review, we survey the present knowledge in this area, with a particular focus on the molecular aspects of adipocyte biology including differentiation, lipid metabolism, thermogenic function and the browning/beiging process